Stockwatch

Date	Sym	Type	Headline
2026-08-03 16:05	UU:CADL	News Release200	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-03 08:05	UU:CADL	News Release200	Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
2026-07-29 08:05	UU:CADL	News Release200	Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston
2026-07-08 16:05	UU:CADL	News Release200	Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01 16:05	UU:CADL	News Release200	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-30 08:05	UU:CADL	News Release200	Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
2026-06-25 08:05	UU:CADL	News Release200	Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
2026-06-02 08:05	UU:CADL	News Release200	Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
2026-06-01 16:05	UU:CADL	News Release200	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 16:05	UU:CADL	News Release200	Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
2026-05-14 08:05	UU:CADL	News Release200	Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-13 08:05	UU:CADL	News Release200	Candel Therapeutics to Present at Upcoming Investor Conferences
2026-05-04 08:05	UU:CADL	News Release200	Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
2026-05-01 16:05	UU:CADL	News Release200	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-29 08:05	UU:CADL	News Release200	Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
2026-04-02 16:05	UU:CADL	News Release200	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-17 08:05	UU:CADL	News Release200	Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
2026-03-12 08:05	UU:CADL	News Release200	Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
2026-03-09 08:05	UU:CADL	News Release200	Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
2026-03-02 16:05	UU:CADL	News Release200	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-24 08:05	UU:CADL	News Release200	Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston
2026-02-19 21:40	UU:CADL	News Release200	Candel Therapeutics Announces Pricing of Public Offering
2026-02-19 16:05	UU:CADL	News Release200	Candel Therapeutics Announces Proposed $100 Million Public Offering
2026-02-19 16:01	UU:CADL	News Release200	Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
2026-02-11 08:05	UU:CADL	News Release200	Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
2026-02-02 16:05	UU:CADL	News Release200	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-17 16:05	UU:CADL	News Release200	Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
2025-11-13 08:25	UU:CADL	News Release200	Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
2025-11-04 09:00	UU:CADL	News Release200	Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
2025-11-03 08:05	UU:CADL	News Release200	Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
2025-10-16 08:05	UU:CADL	News Release200	Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
2025-10-14 08:10	UU:CADL	News Release200	Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
2025-10-14 08:10	UU:CADL	News Release200	Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
2025-10-14 08:05	UU:CADL	News Release200	Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
2025-10-03 09:05	UU:CADL	News Release200	Candel Therapeutics to Present at the SITC 2025 Annual Meeting
2025-09-29 08:05	UU:CADL	News Release200	Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
2025-09-17 08:05	UU:CADL	News Release200	Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
2025-09-02 08:05	UU:CADL	News Release200	Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
2025-08-28 08:05	UU:CADL	News Release200	Candel Therapeutics to Participate in Upcoming Investor Conferences in September
2025-08-14 08:05	UU:CADL	News Release200	Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights